Notch pathway inhibitor DAPT accelerates in vitro proliferation and adipogenesis in infantile hemangioma stem cells

XING XU\textsuperscript{1}, YAO WU\textsuperscript{1}, HONGHONG LI\textsuperscript{1}, JUAN XIE\textsuperscript{1}, DONGSHENG CAO\textsuperscript{1} and XUEYING HUANG\textsuperscript{2}

\textsuperscript{1}Department of Plastic Surgery, The Second Affiliated Hospital of Anhui Medical University; \textsuperscript{2}Department of Anatomy, Anhui Medical University, Hefei, Anhui 230000, P.R. China

Received December 10, 2020; Accepted June 3, 2021

DOI: 10.3892/ol.2021.13115

Abstract. The Notch signaling pathway is crucial in both adipogenesis and tumor development. It serves a vital role in the development and stability of blood vessels and may be involved in the proliferative phase of infantile hemangiomas, which express various related receptors. Therefore, it was hypothesized that the Notch signaling pathway inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), a \(\gamma\)-secretase inhibitor, might help accelerate the regression of infantile hemangiomas. The present in vitro study evaluated whether inhibition of the Notch signaling pathway using DAPT could alter adipogenesis in hemangioma stem cells (HemSCs) derived from infantile hemangioma (IH) specimens. A total of 20 infants (age, \(\leq 6\) months) with hemangiomas who had not yet received any treatment were selected, and their discarded hemangioma tissues were obtained. HemSCs were isolated from the fresh, sterile IH specimens and treated with DAPT. Reverse transcription-quantitative PCR and western blotting were used to demonstrate the inhibition of the Notch signaling pathway by DAPT. A proliferation assay (Cell Counting Kit-8), oil red O staining, flow cytometry and a transwell assay were used to detect proliferation, adipogenesis, apoptosis and migration of HemSCs. Treatment with DAPT upregulated the expression levels of CCAAT/enhancer-binding protein (C/EBP) \(\alpha, \beta\), peroxisome proliferator-activated receptor-\(\gamma\), adiponectin and insulin-like growth factor 1, and promoted the proliferation, apoptosis, migration and lipid accumulation in HemSCs in vitro. Targeting the Notch signaling pathway using DAPT may potentially accelerate the regression of infantile hemangiomas.

Introduction

Hemangioma is the most common benign tumor in infants and involves a localized angiogenic lesion (1). The lesion typically forms \(\sim 2\) weeks after birth, grows for 6-10 months, and subsequently regresses, being gradually replaced by fibrous adipose tissue in the next 7-10 years (2). However, \(\sim 10\%\) of patients experience persistent hemangioma, which can lead to disfiguration, blindness and even death (3).

Promoting adipogenesis in hemangioma stem cells (HemSCs) may accelerate hemangioma regression (4). The Notch, VEGF, angiopoietin, mTOR and Bax-mediated signaling pathways have been associated with hemangioma regression (5). Compared with other options of mechanism of action, there are only a few studies on the association between the Notch signaling pathway and infantile hemangioma (IH) (6,7). The Notch signaling pathway may serve a role in the occurrence and development of infantile hemangiomas (6,7). However, to the best of our knowledge, the effect of Notch inhibition by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) on IH has not been investigated. Although there may be a few scars and disfigurements, this treatment will produce fewer side effects and adverse reactions, and is more consistent with the natural progression of diseases (8). Furthermore, the expression levels of Jagged-1 and Notch-4 are increased during the proliferative phase (9), and the expression levels of Notch-1-4 and some of its ligands [delta-like 4 (DLL-4) and Jagged-1] are upregulated during the hyperplastic and regression stages (10). In addition, the Notch expression pattern can reflect vascular development from immature cells to endothelial lines (11).

The Notch signaling pathway influences cell-cell contact, proliferation, differentiation and apoptosis (12). It is highly conserved and composed of four receptors (Notch-1-4) and five ligands (Jagged-1 and -2, DLL-1, DLL-3, and DLL-4), which serve important roles in vascular development and differentiation (13-15). The expression levels of DLL-4 are increased in tumor endothelial cells (16), and act as a negative regulator of tumor angiogenesis (17). Therefore, abnormal DLL-4 expression in tumor endothelial cells can lead to arteriovenous...
Isolation and identification of HemSCs. The study protocol was approved by the Ethics Committee of The Second Affiliated Hospital of Anhui Medical University (approval no. YX2020-050F1; Hefei, China). Written informed consent was obtained from the guardians of the patients.

Infant hemangioma tissues were collected from 20 infants (age range, 0-6 months; median age, 4 months) with hemangioma who were yet to receive any treatment and were hospitalized between January 2018 and December 2019 at The Second Affiliated Hospital of Anhui Medical University (Hefei, China). Among the 20 infants, 9 were male patients and 11 were female patients. The inclusion criteria were as follows: i) Age ≤6 months; ii) specimen confirmed as hemangioma by clinicians and pathologist and was in the proliferative phase (35); and iii) written informed consent was obtained from the legal guardians of the patients. Hemangioma tissues were surgically resected and stored immediately in DMEM (Cytiva) with high glucose, 10% FBS (Biological Industries) and 1% penicillin-streptomycin (Beyotime Institute of Biotechnology) at 4°C. Fat and skin tissues were removed, and the specimens were washed three times using PBS (Beyotime Institute of Biotechnology) before being cut into 0.1-mm slices. The slices were digested at 37°C for 2 h in water and 0.2% Collagen R solution (SERVA Electrophoresis GmbH). The sample was strained twice using a 100-µm filter, and CD133-positive HemSCs were collected from the resulting suspension using the magnetic bead technique (36). The purified HemSCs were cultured at 37°C with 5% CO₂ using endothelial cell medium (ECM; ScienCell Research Laboratories, Inc.) supplemented with 10% FBS and 1% penicillin-streptomycin (PS). The presence of CD133 in the cells was confirmed by a BD LSR II flow cytometer (Becton, Dickinson and Company) using TruCountTM tubes (BD Biosciences). The absolute count of the cell population was obtained using FlowJo Analysis Software V10 (Tree Star, Inc.).

DAPT treatment and proliferation assay. For the proliferation assay, HemSCs were seeded into 96-well plates (Corning, Inc.) at a density of 1.0x10³ cells/well. After 24 h of serum starvation, DAPT (Beyotime Institute of Biotechnology) was added at concentrations of 0, 10, 20, 40 and 60 µM, and the cells were cultured at 37°C for 72 h. Subsequently, Cell Counting Kit-8 (CCK-8) reagent (Dojindo Molecular Technologies, Inc.) was added to the culture and incubated for 4 h. Then, absorbance was measured at 490 nm using a microplate reader (ELx800; BioTek Instruments, Inc.). Another set of cells were then similarly recultured and treated with the optimum DAPT concentration that resulted in the highest absorbance in the previous culture for 0, 24, 48, 72 and 96 h, followed by the CCK-8 assay, as aforementioned. Subsequently, HemSCs were seeded at a density of 1x10⁶ cells/ml into 6-well plates (Corning, Inc.) and cultured until they reached 50-60% confluence. The HemSCs were then starved in a serum-free medium for 24 h, and treated with DAPT at concentrations of 2.5, 5, 10, 20 and 40 µM, which were prepared from a stock solution in DMSO (Beyotime Institute of Biotechnology). The final concentration of DMSO in the culture medium was <0.25%. After 24 h of DAPT treatment in a 37°C incubator with 5% CO₂, the medium was changed to a DAPT-free medium. The optimal concentration (40 µM) of DAPT that resulted in the lowest measurable expression of Notch-1 and -3 and the strongest cell viability was used for subsequent experiments. The medium was changed every 24 h.
Table I. Primer sequences used for reverse transcription-quantitative PCR.

| Gene      | Sequence (5'-3')                                                                 |
|-----------|----------------------------------------------------------------------------------|
| Notch-1   | F: AACAGCGAGGAAGGAGGAGGA R: GCATCAGAGGCTGAGTACGC                                  |
| Notch-3   | F: ATCCGCTCGATGGATATG R: ACCCTCAAGGTAGTCA                                       |
| β-actin   | F: CTGGAACGGTGAAAGGTGAC R: AAGGACACTTCTGGATCAAATGCA                              |
| Notch-4   | F: ACCTCCAAAGGTGACTCA                                                            |

Table II. Primer sequences used for reverse transcription-quantitative PCR.

| Gene       | Sequence (5'-3')                                                                 |
|------------|----------------------------------------------------------------------------------|
| PPARγ      | F: CCATCCGCATCTTTCA R: GAAGTATTGGTCT                                               |
| C/EBPα     | F: GTTGGAACAGAAACAGCAAGAGT R: CCAGACCTTTCTGCGTCT                                   |
| C/EBPβ     | F: GGGCAAGACCTGGAAGAAGGCC R: GCTCTGGTAGCCGGAGTAA                                   |
| Adiponectin| F: AAGGGACATCGGTTGAA R: AAGTAGTACAGGCCAGGAAT                                    |
| IGF-1      | F: TATITCAACAAGGCCCACAG R: ATACATTCTCAGCTCCTTTA                                   |
| β-actin    | F: GCCACCCCAGCAATGGA R: TAGAAGCAATTTGGG                                           |

Adipogenic differentiation. DAPT (40 µM)-treated HemSCs were evaluated by seeding 5.0x10^5 cells in 6-well plates at 37°C for 24 h. The standard medium (ECM plus 10% FBS and 1% PS) was replaced with an adipogenic differentiation medium (GUXMX-90031; Cyagen Biosciences, Inc.). The cells were cultured in the adipogenic differentiation medium in a 37°C incubator with 5% CO₂ for 14 days, and the medium was replaced every 72 h.

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from HemSCs using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and mRNA was reverse transcribed into cDNA using the PrimeScript™ RT kit (Takara Biotechnology Co., Ltd.), all steps were performed on ice. Reverse transcription was conducted at 37°C for 15 min, followed by 85°C for 5 sec and 4°C for 10 min for heat inactivation. The expression levels of Notch-1 and Notch-3 at different DAPT concentrations were measured, and then the expression levels of proliferator-activated receptor-γ (PPARγ), CCAAT/enhancer-binding protein (C/EBP) α, C/EBPβ, adiponectin and insulin-like growth factor 1 (IGF-1) at the same concentration were measured after the optimal concentration was determined. The expression levels of Notch-1, Notch-3, peroxisome PPARγ, C/EBP α, C/EBPβ, adiponectin and IGF-1 were quantified using β-actin as an endogenous control. The CFX Connect Real-Time System (Bio-Rad Laboratories, Inc.) was used for RT-qPCR according to the manufacturer's protocol, as follows: Preheating at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min, extension at 72°C for 35 sec, and 4°C for preservation. The results were normalized to β-actin expression levels, and the samples were analyzed in triplicate (37). Analysis of relative gene expression data was obtained by RT-qPCR using the 2^ΔΔCq method (38). The primer sequences are shown in Table I (Notch-1 and -3) and Table II (PPARγ, C/EBP α, C/EBPβ, adiponectin and IGF-1). Each reaction was performed in duplicate in a total volume of 20 µl, containing 1 µl cDNA, 10 µl SYBR® Premix Ex Taq II (Takara Biotechnology Co., Ltd.), 1 µl of each primer pair and 7 µl DNase/RNase-free water (Beijing Solarbio Science & Technology Co., Ltd.). The relative mRNA expression levels were measured using the 2^ΔΔCq method (37) in triplicate.

Western blot analysis. HemSCs were cultured at 37°C for 24 h after 24 h of treatment with DAPT at varying concentrations (2.5, 5, 10, 20 and 40 µM) at 37°C and then homogenized in RIPA buffer (Beyotime Institute of Biotechnology) containing protease inhibitors (Pierce; Thermo Fisher Scientific, Inc.). The lysate was centrifuged at 4°C in 16,099 x g for 30 min to remove cell fragments, and the protein-containing supernatant was boiled in a sample protein buffer for 10 min. A Bradford Protein Assay kit (Beyotime Institute of Biotechnology) was utilized to determine the protein concentrations. The protein extracts (73 µg/lane) were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (Wuhan Servicebio Technology Co., Ltd.) on 10% polyacrylamide gels, and separated proteins were transferred to a polyvinylidene fluoride membrane (Cell Signaling Technology, Inc.). The membranes were blocked with 0.24% Tween-20 containing 5% non-fat milk for 2 h at room temperature, and incubated with primary antibodies targeting β-actin (dilution, 1:1,000; cat. no. AF7018; Affinity Biosciences), Notch-1 (dilution, 1:500; cat. no. W01991; Wanleibio Co., Ltd.) and Notch-3 (dilution, 1:500; cat. no. W02051; Wanleibio Co., Ltd.) at 4°C overnight. The optimal concentration of DAPT was selected based on the lowest expression levels of Notch-1 and -3, as measured by RT-qPCR and western blotting. Additional cultures were prepared and protein samples were collected to evaluate the effects of DAPT treatment on the expression levels of β-actin (dilution, 1:1,000; cat. no. 3700; Cell Signaling Technology, Inc.), PPARγ (dilution, 1:500; cat. no. BS-0530R-2; BIOSS), C/EBPα (dilution, 1:1,000; cat. no. BS-1396R; BIOSS), adiponectin (dilution, 1:1,000; cat. no. BS-0471R; BIOSS) and IGF-1 (dilution, 1:1,000; cat. no. BS-0014R; BIOSS). Membranes were incubated with horseradish peroxidase-conjugated secondary antibody (cat. no. ZB2301; OriGene Technologies, Inc.) mixed with TBS with 0.24% Tween-20 at a ratio of 1:10,000 for 1 h at 37°C. The signal was detected using enhanced chemiluminescence.
reagents (Beyotime Institute of Biotechnology), and protein expression was semi-quantified based on grayscale analysis using ImageJ software (version 1.51s; National Institutes of Health).

**Oil red O staining.** After 14 days of adipogenic differentiation, the cells were washed with PBS and fixed in 4% paraformaldehyde at 37°C for 40 min. After the third wash, cells were stained for 10 min using a 40:60 mixture of water and a solution containing oil red O (100 ml isopropyl alcohol and 0.5 g oil red O; Sigma-Aldrich; Merck KGaA) and filtered at 37°C for 30 min. The cells were observed and images were captured using an inverted light microscope (Nikon Corporation), and droplets were quantified using ImageJ software. The Oil Red O-stained cells were quantified using ImageJ software. Data are presented as the average percentage of the maximum signal %.

**Apoptosis assay.** To evaluate apoptosis, HemSCs were seeded at a density of 1.0x10^6 cells/well into 6-well plates (Corning, Inc.) and treated with 40 µM DAPT at 37°C for 24 h, followed by staining with fluorescein isothiocyanate isothiocyanate-bound annexin V and propidium iodide (apoptosis detection kit; Beyotime Institute of Biotechnology). Cells were harvested and counted in a volume of 100 µl on a BD LSR II flow cytometer (Becton, Dickinson and Company) using TruCountTM tubes (BD Biosciences). Flow cytometry was used to determine the proportion of apoptotic cells. ModFit L T (4.0; Verity Software House, Inc.) was used in quantitative analysis of apoptosis. Additional cultures were prepared, and the cells were cultured in the adipogenic differentiation medium for 14 days after DAPT treatment. Subsequently, the cells were collected, and apoptosis was examined again by flow cytometry.

**Transwell assay.** Migration was evaluated at 37°C using 24-well Transwell inserts with ECM (600 µl) containing 30% FBS in the lower chambers. After 24 h of treatment with DAPT, 2x10^4 HemSCs were added to 200 µl DMEM in the upper chambers at room temperature. After another 24 h of incubation at 37°C, the cells in the bottom chambers were washed twice with PBS, fixed with 4% paraformaldehyde for 30 min and stained with a 0.1% crystal violet solution for 10 min at room temperature. After three washes with PBS, the cells were observed under a light microscope (magnification, x100) and the migratory cells were quantified using ImageJ software. Data are presented as the average percentage of the maximum signal %.

**Statistical analysis.** Data are presented as the mean ± standard deviation (n=3 for each experiment) and were analyzed using IBM SPSS software (version 23; IBM Corp.). An unpaired Student’s t-test was used to assess the differences between two groups, for multiple groups, one-way analysis of variance followed by Bonferroni statistical tests was used to assess the mean values. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Optimal concentration of DAPT for inhibition of the Notch signaling pathway.** HemSCs were identified by flow cytometry. After magnetic bead sorting, the CD133 positivity rate of the first generation of hemangioma stem cells was 7.20%, and that of the third generation was 1.13%.

**Effects of DAPT on HemSCs.** Adipogenic differentiation for 14 days followed by DAPT treatment increased adiponectin (Fig. 3A), C/EBPα (Fig. 3B), C/EBPβ (Fig. 3C) and PPARγ (Fig. 3D) mRNA and protein (Fig. 3F) expression compared with the DMSO and the blank control groups. DAPT-treated
cells exhibited higher expression levels of adiponectin (Fig. 3G), C/EBPα (Fig. 3H), C/EBPβ (Fig. 3I), and PPARγ (Fig. 3J) than those in the control groups (CON, ADIP and ADIP+DMSO). DAPT-treated adipogenic cells exhibited the highest expression levels of IGF-1, which were significantly higher than the other three control groups (Fig. 3E and K), whereas treatment with DMSO alone did not significantly influence the expression levels of IGF-1 compared with those of the ADIP group.

It was also observed that treatment with DAPT increased the number and size of adipocytes based on oil red O staining of HemSCs after 14 days of adipogenic differentiation. The size of Oil Red O-stained cells was quantified using Image J software (Fig. 4A and B). DAPT-treated adipogenic cells had the highest number and largest size of lipid droplets, whereas treatment with DMSO alone did not significantly influence the expression levels of IGF-1 compared with those of the ADIP group.

Discussion

The inhibition of Notch signaling was proportional to the concentrations of DAPT used (2.5-40 µM). DAPT at 40 µM induced the greatest proliferation among all groups in the cell proliferation assay (0-60 µM; Fig. 5B). Therefore, the greatest inhibitory effect and proliferation were induced when the concentration of DAPT was 40 µM. Therefore, all other experiments were performed using a DAPT concentration of 40 µM. The proportions of apoptotic cells were not significantly different between the groups cultured in adipogenic medium with DMSO and those cultured in adipogenic medium without DMSO (Fig. 5A). However, the proportion of apoptotic cells was the highest in the group cultured in DAPT-containing adipogenic medium, and the proportion of apoptotic cells was the lowest in the group cultured in no-treatment medium. The three adipogenesis groups (ADIP, ADIP+DMSO and ADIP+DAPT) also had higher proportions of apoptotic cells, and there was no difference observed between the control and DMSO groups (Fig. 5A). Based on the absorbance values at 490 nm in the CCK-8 assay, DAPT stimulated the proliferation of HemSCs (days 1-5) when compared with the control group. The highest absorbance value was observed in the DAPT-treated group, and the proliferation of DAPT-treated HemSCs (days 3-5) was particularly promoted compared with that of the untreated group (Fig. 5C). Furthermore, there was no significant difference in proliferation between the DMSO and control groups.

The Notch signaling pathway is essential in regulating various biological functions, tumor growth (39), vascular endothelial cell proliferation and adipogenesis (10,40). Previous studies have demonstrated that inhibition of the Notch signaling pathway can promote adipogenesis in cells (41,42). DAPT inhibits Notch receptor enzymatic hydrolysis, intracellular domain release and
transcriptional activation by inhibiting γ-secretase activity (43). It effectively blocks the signal from Notch receptor and thus inhibits the activation of the Notch signaling pathway (30). DAPT has also been documented to have little effect on other cellular signaling pathways (44). Previously, γ-secretase inhibitors were mainly used to treat Alzheimer’s disease (45); however, they have also been demonstrated to inhibit lung, breast, colorectal and pancreatic cancer (46-49). However, deletion of Notch functional mutations in hepatocellular carcinoma and melanoma has established its role as a tumor suppressor (50). The activation of the Notch signaling pathway inhibits adipogenesis through autophagy activation and the PTEN-PI3K/AKT/mTOR signaling pathway (20). The Notch signaling pathway inhibitors suppress this process and promote adipocyte differentiation (19-20,51). It was hypothesized that the inhibition of the Notch signaling pathway might influence the proliferation of HemSCs and this hypothesis was examined by measuring cell proliferation after treatment with five concentrations of DAPT (0, 10, 20, 40 and 60 µM). In the range of 0-40 µM, HemSCs were in the proliferative state; however, when the concentration of DAPT rose to 60 µM, the proliferation decreased. The greatest reduction in Notch-1 and -3 mRNA and protein expression was observed at a DAPT concentration of 40 µM; however, concentration-dependent inhibition was
observed in the range of 2.5-40 µM, suggesting that there is a dose-response relationship.

The regression of IH occurs due to simultaneous increase in apoptosis and adipogenesis (52). The Bcl-2 family members, Bcl-2, Bcl-x (53), giant seaperch iridovirus serine/threonine kinase (54) and voltage-dependent anion channel 2 (55), are also mainly associated with apoptosis through a Bax-mediated mechanism. The Notch signaling pathway serves an important role in angiogenesis and tumorigenesis, and only a few studies have investigated the role of Notch signaling in tumor regression (56,57). The present data indicated that DAPT inhibited Notch signaling and could accelerate adipogenesis and apoptosis in IH. Adipogenesis is regulated by a variety of factors, including C/EBP\(\alpha\), C/EBP\(\beta\), PPAR\(\gamma\) and adiponectin (58). The C/EBP\(\alpha\) molecules serve different roles in regulating adipocyte differentiation (59): In pre-adipocytes, C/EBP\(\beta\) accelerates the induction of C/EBP\(\alpha\), which is an important part of the genetic cascade leading to adipogenesis (60). C/EBP\(\alpha\) is an adipogenic transcription factor, which cannot independently induce adipogenesis and requires the co-activity of PPAR\(\gamma\), which is a transcription factor that can independently induce adipogenic differentiation (61). Additionally, adiponectin promotes pre-adipocyte differentiation via the PPAR\(\gamma\) signaling pathway (62). Cell proliferation, differentiation and apoptosis depend on activation of the IGF-1 signaling pathway (63). IGF-1 serves an important role in fat formation in HemSCs arising from IH and may be of interest for the treatment of IH (64).

However, at present, the present fundamental research is only at the cell level and has not yet been certified in clinical trials. This will be investigated in subsequent studies.

The IGF-1 polypeptide has multiple binding sites and can help regulate tumor development, growth and metastasis by inhibiting apoptosis, advancing the cell cycle and regulating angiogenesis (65). Furthermore, our previous study revealed that IGF-1 regulates adipogenesis and proliferation of HemSCs, which may involve the IGF-1 receptor and PI3K signaling pathways (66).

Given the inter-relatedness of the aforementioned processes, it was hypothesized that DAPT may accelerate IH regression via the Notch and IGF-1 signaling pathways, and this hypothesis was examined in the present in vitro study.

A previous study has indicated that linsitinib (OSI-906, an IGF-1 receptor inhibitor) can reduce the expression of C/EBP\(\alpha\), C/EBP\(\beta\), PPAR\(\gamma\) and adiponectin (67). In the present study, treatment with DAPT increased the expression levels of IGF-1 in HemSCs. It was hypothesized that the IGF-1 signaling pathway also influences adipogenesis in infantile hemangioma. Therefore, treatment with DAPT may be useful for driving the regression of IH by influencing IGF-1 signaling.

One of the limitations of the present study was that the upper concentration limit for the inhibitory effects of DAPT was not established. In addition, only in vitro experiments were performed to characterize the effects of treatment with DAPT.
on adipogenesis in HemSCs. Therefore, further animal-based *in vivo* studies are required to confirm the present hypothesis that DAPT may help drive hemangioma regression via the Notch and IGF-1 signaling pathways.

In conclusion, treatment with DAPT regulated the proliferation and differentiation of HemSCs and promoted adipogenesis, which was associated with the induction of the IGF-1 signaling pathway. Comparison of adipogenic and nonadipogenic groups revealed that adipogenesis increased the apoptosis of HemSCs, and DAPT upregulated apoptosis. In addition, the DAPT-treated adipogenic group of HemSCs exhibited higher expression levels of C/EBPα, C/EBPβ, PPARγ and adiponectin than the control group. Therefore, inhibition of the Notch signaling pathway using DAPT may contribute to apoptosis and proliferation, as well as adipogenesis in HemSCs. This may help drive the regression of IH. However, further studies are required to validate these observations and potentially help develop a treatment strategy to accelerate the regression phase of IH.

**Acknowledgements**

Not applicable.

**Funding**

The present study was supported by the Natural Science and Technology Fund Project of the Anhui Province (grant no. 1808085MH282).
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

DC and XH designed the experiments. XX performed the experiments and wrote the manuscript. HL, JX and YW analyzed the experimental data. DC and XH confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Anhui Medical University (approval no. YX2020-050F1; Hefei, China). Written informed consent was obtained from the guardians of the patients.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Wu KQ, Muratore CS, So EY, Sun C, Dubielecka PM, Reginato AM and Liang OD: M1 macrophage-induced endothelial-to-mesenchymal transition promotes infantile hemangioma regression. Am J Pathol 187: 2102-2111, 2017.
2. Darrow DH, Greene AK, Mancini AJ and Nopper AJ: Section on Dermatology, Section on Otolaryngology-Head & Neck Surgery, and Section on Plastic Surgery: Diagnosis and management of infantile hemangioma: Executive summary. Pediatrics 136: 786-791, 2015.
3. Bischoff J: Progenitor cells in infantile hemangioma. J Cranioc  Surg 20 (Suppl 1): S695-S697, 2009.
4. Wong A, Hardy KL, Kitajewski AM, Shawber CJ, Kitajewski JK and Wu JK: Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. Plast Reconstr Surg 150: 1012-1021, 2012.
5. Ji Y, Chen S, Li K, Li L, Xu C and Xiang B: Signaling pathways in the development of infantile hemangioma. J Hematol Oncol 7: 13, 2014.
6. Shen W, Huang J and Wang Y: Biological significance of NOTCH signaling strength. Front Cell Dev Biol 9: 652273, 2021.
7. Pierscianek D, Wolf S, Keyvani K, El Hindy N, Stein KP, Sandalcioglu IE, Sure U, Mueller O and Zhuz Y: Study of angiogenic signaling pathways in hemangioblastoma. Neuropathology 37: 3-11, 2017.
8. Baselga Torres E, Bernabéu Wittel J, van Esso Arbolave DL, Febrer Bosch MI, Carrasco Sanz A, de Lucas Laguna R, Del Pozo Losada J, Hernández Martín A, Jiménez Montañés L, Lázaro Gutiérrez JC, et al: Spanish consensus on infantile haemangioma. An Pediatr (Barc) 85: 256-265, 2016 (In Spanish).
9. Calicchio ML, Collins T and Kozakiewicz HP: Identification of signaling systems in proliferating and involving phase infantile hemangiomas by genome-wide transcriptional profiling. Am J Pathol 174: 1638-1649, 2009.
10. Wu JK and Kitajewski JK: A potential role for notch signaling in the pathogenesis and regulation of hemangiomas. J Craniolac Surg 20 (Suppl 1): S698-S702, 2009.
11. Wu J, Adepoju O, De Silva D, Baribault K, Boscolo E, Bischoff J and Kitajewski J: A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma. Angiogenesis 13: 15-23, 2010.
12. Gama-Norton L, Ferrando E, Ruiz-Herguido C, Liu Z, Guit J, Islam AB, Lee SU, Yan M, Guidos CÍ, López-Bigas N, et al: Notch signal strength controls cell fate in the haemogenic endothelium. Nat Comm 6: 8510, 2015.
13. Zhang P, Yan X, Chen Y, Yang Z and Han H: Notch signaling in blood vessels: From morphogenesis to homeostasis. Sci China Life Sci 57: 774-80, 2014.
14. Kopan R and Ilagan MX: The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 137: 216-233, 2009.
15. Grant ZL and Coultas L: Growth factor signaling pathways in vascular development and disease. Growth Factors 37: 53-67, 2019.
16. Mailhols C, Modlich U, Lewis J, Harris A, Bicknell R and Ish-Horowiz D: Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69: 135-144, 2001.
17. Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL and Lewis J: Endothelial signaling by the notch ligand Delta-like-4 restricts angiogenesis. Development 134: 839-844, 2007.
18. Goruganthulu MUL, Shanker A, Dick MM and Carbone DP: Specific targeting of Notch ligand-receptor interactions to modulate immune responses: A review of clinical and preclinical findings. Front Immunol 11: 1958, 2020.
19. Zhang H, Wei T, Johnson A, Sun R, Richter G and Strub GR: NOTCH pathway activation in infantile hemangiomas. J Vase Surg Venous Lymphat Disord 9: 489-496, 2021.
20. Song BQ, Chi Y, Li X, Du WJ, Han ZB, Tian JJ, Li JJ, Chen F, Wu HH, Han LX, et al: Inhibition of Notch signaling promotes the adiopogenic differentiation of mesenchymal stem cells through autophagy activation and PTEN-PISK/AKT/mTOR pathway. Cell Physiol Biochem 36: 1991-2002, 2015.
21. Sandel DA, Liu M, Gobbonay N and Newman JH: Notch3 is involved in angiogenesis of human adipose-derived stromal/stem cells. Biochemie 150: 31-36, 2018.
22. Chaturvedi BS, Palliyaguru DL, Wakabayashi N, Khoo NK, Schooswolh O, Doherty RM and Kessler TW: Notch intracellular domain overexpression in adipocytes confers lipidopropy in mice. Mol Metab 4: 543-550, 2015.
23. Nandagopal N, Santal LA and Elowitz MB: Cis-activation in the Notch signaling pathway. Nature 563: 213-217, 2018.
24. van Tetering G and Vooijs M: Proteolytic cleavage of Notch: ‘HIT and RUN’. Curr Mol Med 11: 255-269, 2011.
25. Sprinzak D and Blacklow SC: Biophysics of Notch signaling. Annu Rev Biophys 50: 157-189, 2021.
26. Dong Z, Huo J, Liang A, Chen J, Chen G and Liu D: Gamma-Secretase Inhibitor (DAPT), a potential therapeutic target drug, caused neurotoxicity in planar regimen by inhibiting Notch signaling pathway. Sci Total Environ 781: 146735, 2021.
27. Menapace D, Mitkov M, Towbin R and Hogeling M: The changing face of complicated infantile hemangioma treatment. Front Endocrinol (Lond) 134: 1555-1572, 2020.
28. Chen ZY, Wang QN, Zhu YH, Zhou LY, Xu T, He ZY and Yang Y: Progress in the treatment of infantile hemangioma. Ann Transl Med 7: 692, 2019.
29. Dai G, Deng S, Guo W, Yu L, Yang J, Zhou S and Gao T: Notch signaling pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antimumor effect of cisplatin in resistant osteosarcoma. Mol Carcinog 58: 3-18, 2019.
30. Hans CP, Sharma N, Dev R, Blain JM,Tonninges J and Agarwal G: DAPT, a potent Notch inhibitor regresses actively growing abdominal aortic aneurysm via divergent pathways. Clin Sci (Lond) 134: 1555-1572, 2020.
31. Kangsamaksin T, Mutromaki A, Koeller NM, Cuervo H, Caudhri RA, Tattersall IW, Rosenstiel PE, Shawber CJ and Kitajewski J: NOTCH decoys that selectively block DLL/NOTCH cooperativity and inhibit functional angiogenic signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Am J Pathol 174: 1638-1649, 2009.
32. Wu JK and Kitajewski JK: A potential role for notch signaling in the pathogenesis and regulation of hemangiomas. J Craniolac Surg 20 (Suppl 1): S698-S702, 2009.
33. Wu J, Adepoju O, De Silva D, Baribault K, Boscolo E, Bischoff J and Kitajewski J: A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma. Angiogenesis 13: 15-23, 2010.
35. van der Vleuten CJM and Raphael MF: Infantile haemangioma; refer and treat on time. Ned Tijdschr Geneeskd 163: D3700, 2019 (In Dutch).
36. Li Y, Li X, Xie J, Wang F, Cao D and Lou Y: MiR-139-5p affects cell proliferation, migration and adipogenesis by targeting insulin-like growth factor 1 receptor in hemangioma stem cells. Int J Mol Med 45: 569-577, 2020.
37. Picard A, Boscolo E, Khan ZA, Bartch TC, Mulliken JB, Vazquez MP and Bischoff J: IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal reveal similarities between congenital and common infantile hemangioma. Pediatr Res 63: 263-267, 2008.
38. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
39. Zhang K, Wang F, Huang J, Lou Y, Xie J, Li H, Cao D and Huang X: Insulin-like growth factor 2 promotes the adipogenesis of hemangioma-derived stem cells. Exp Ther Med 17: 1663-1669, 2019.
40. Li L, Tang P, Li S, Qin X, Yang H, Wu C and Liu Y: Notch signaling pathway networks in cancer metastasis: A new target for cancer therapy. Med Oncol 34: 180, 2017.
41. Ba K, Yang X, Wu L, Wei X, Fu N, Fu Y, Cai X, Yao Y, Ge Y and Lin Y: Jagged-1-mediated activation of notch signaling induces adipogenesis of adipose-derived stem cells. Cell Prolif 45: 538-543, 2012.
42. Boucher JM, Ryzhova L, Harrington A, Davis-Knolton J, Turner JE, Cooper E, Maridas D, Ryzhov S, Rosen CJ, Vary CPH and Liaw L: Pathological conversion of mouse perivascular adipose tissue by notch activation. Arterioscler Thromb Vasc Biol 40: 2227-2243, 2020.
43. Yin X, Wei H, Wu S, Wang Z, Liu B, Guo L, Bi H and Guo D: DAPT reverses the Th17/Treg imbalance in experimental autoimmune uveitis in vitro via inhibiting Notch signaling pathway. Int Immunopharmacol 79: 106107, 2020.
44. Sun W, Li J, Li Y, Zheng J, Zhang X, Huang X and Li S: Gamma-secretase inhibitor, DAPT, prevents the development of retinopathy of prematurity in a rat model by regulating the Delta-Like Ligand 4/Notch Homolog-1 (DLL4/Notch-1) pathway. Med Sci Monit 25: 492-499, 2019.
45. Svedružić ŽM, Popović K and Sendula-Jengić V: Modulators of β-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer's disease. PLoS One 8: e50759, 2013.
46. Wang M, Ma X, Wang J, Wang L and Wang Y: Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling. Int J Oncol 44: 1401-1409, 2014.
47. Su F, Zhu S, Ruan J, Mutufoglu Y, Zhang L and Yuan Q: Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer. Oncotarget 7: 4142-4154, 2016.
48. Mori M, Miyamoto T, Yukushii H, Ohno S, Miyake Y, Sakaguchi T, Hattori M, Hongo A, Nakaizumi A, Ueda M and Ohno E: Effects of N-[(3,5-difluorophenacetyl-L-alanyl)-S-phenylglycine t-buty1 ester] (DAPT) on cancer proliferation and apoptosis in Ishikawa endometrial cancer cells. Hum Cell 25: 9-15, 2012.
49. Li JY, Li RJ and Wang HD: γ-secretase inhibitor DAPT sensitizes t-AUCB-induced apoptosis of human glioblastoma cells in vitro via blocking the p38 MAPK/MAPKAPK2/HS2p27 pathway. Acta Pharmacol Sin 35: 825-831, 2014.
50. Hubmann R, Sieghart W, Schnabl S, Araghi M, Hilgarth M, Reiter M, Demirtas D, Valenti F, Zielinska C, Jäger U and Schadendorf D: Gliotoxin targets nuclear NOTCH2 in human solid tumor derived cell lines in vitro and inhibits melanoma growth in xenograft mouse model. Front Pharmacol 8: 319, 2017.
51. Rodríguez-Cano MM, González-Gómez MJ, Sánchez-Solana B, Monsalve EM, Díaz-Guerra MM, Laborda J, Nueda ML and Baladrón V: NOTCH receptors and DLK proteins enhance brown adipogenesis in mesenchymal CH101T/2 cells. Cells 9: 2032, 2020.
52. Marey HM, Elmazar HF, Mandour SS and Khairy HA: Combined oral and topical beta blockers for the treatment of early proliferative superficial pericellular infantile capillary haemangioma. J Pediatr Ophthalmol Strabismus 55: 37-42, 2018.